LONDON, September 9, 2016 /PRNewswire/ --
BTG plc (LSE: BTG), an international specialist healthcare
company, today announced the launch of the βETA™ Radiation Safety
Programme, a new initiative designed to reduce the risk of
radiation exposure when performing selective internal radiation
therapy (SIRT) with 90Y microspheres. Developed in
collaboration with global experts, including Professor Jacob Kamen of the Mount Sinai Medical Center,
the βETA™ Radiation Safety Programme analyses current practise and
exposure risk, and provides recommendations to improve safety for
healthcare professionals and patients.
(Logo:
http://photos.prnewswire.com/prnh/20160203/329110LOGO )
The βETA™ Radiation Safety Programme, launching at the 2016
CIRSE (Cardiovascular and Interventional Radiological Society of
Europe) International Conference
in Barcelona, Spain is a new
online resource featuring a range of educational tools and
materials on radiation protection, health and safety. Uniquely, the
resource provides users with proprietary audit tools to assess the
risk of radiation exposure associated with selective internal
radiation therapy (SIRT) with 90Y microspheres. It
offers advice and guidance on reducing exposure levels for
healthcare professionals and patients pre, during and post
procedure. In addition, the βETA™ Radiation Safety Programme
includes a collaborative feedback tool for users to add best
practice experience, ensuring the resource is continually updated
and expert knowledge is shared.
"With the rapid pace of development of new radiation treatments,
there is a real need for education on best practice which is
current to treatments being used today, such as SIRT," said
Professor Jacob Kamen, Chief
Radiation and Laser Safety Officer, Associate Professor of
Radiology at Mount Sinai Medical Center, New York, US. "This need for continual
education requires a resource that is easy to access at any time,
from anywhere, and is updated regularly. The development of the
βETA™ Radiation Safety Programme is informed by expert views from
many of the leading global experts on radiation risk, and has been
designed to ensure that this expert knowledge can be applied
directly to current clinical practice."
Information regarding the βETA™ Radiation Safety Programme is
available via the BTG booth at CIRSE 2016. Healthcare professionals
can access the programme at http://www.btg-beta.com.
-ENDS-
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local,
no company endeavors to do more than BTG Interventional Medicine to
help doctors in their quest to see more, reach further and treat
smarter. Our growing portfolio of Interventional Medicine products
is designed to advance the treatment of liver tumors, advanced
emphysema, severe blood clots, and varicose veins. To learn more
about BTG Interventional Medicine, please visit: btg-im.com.
For further information contact:
BTG plc
Chris Sampson,
Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178
Media Liaison
Jonathan Kearney
+44 208 618 2755; Mobile: +44 7725 925 841
SOURCE BTG plc